TAZVERIK® (tazemetostat) demonstrated meaningful and sustained responses for relapsed or refractory (R/R) follicular lymphoma (FL) patients, in both MT and WT EZH2 populations studied1

Tazemetostat (TAZVERIK®) is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas with a category 2A recommendation as an option for appropriate patients with R/R FL.2

View the efficacy of TAZVERIK

See how TAZVERIK demonstrated efficacy, regardless of EZH2 mutation status.

View the safety data of TAZVERIK

Learn more about how safety and tolerability were evaluated in the trial.

Questions about TAZVERIK?

Epizyme is here to help. Request to have a representative contact you.

EZH2=enhancer of zeste homologue 2; MT=mutant type; WT=wild type.

References: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed February 23, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.